Marisa Wexler, MS, senior science writer —

Electrical stimulation of the brain through electrodes placed on the scalp may ease some measures of spasticity for people with relapsing-remitting multiple sclerosis (RRMS), according to results from a small clinical trial. Using this novel route of brain stimulation was shown to impact muscle contractions in patients with spasticity…

Autologous hematopoietic stem cell transplant (aHSCT) reduces markers of nerve fiber and myelin damage in people with relapsing-remitting MS (RRMS), according to a small study done in Sweden. “We investigated if therapeutic intervention with aHSCT could halt the injurious process leading to tissue damage in MS,” researchers wrote.

Guar gum, a type of dietary fiber that can be taken as a supplement, lessened inflammation and disease severity in a mouse model of multiple sclerosis (MS), a new study reports. While fiber-rich diets have long been recommended to improve overall health, these findings help pinpoint which fibers have…

A quick MRI-based method called SyMRI may be useful in future clinical trials to test experimental myelin-repairing therapies in diseases like multiple sclerosis (MS), a new study shows. The study, “Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging,” was published in Brain…

The Overall Disability Response Score, a combination of three different assessments of disability, could be used to more accurately evaluate the effectiveness of treatments in multiple sclerosis (MS) clinical trials, a new study illustrates. The score is composed of three measures commonly used to assess disability in MS, which…

A new machine learning tool could help make clinical trials for progressive forms of multiple sclerosis (MS) more efficient and effective, a study suggests. Its scientists propose that the tool, when used in initial patient studies, works to more rapidly move a potential progressive MS treatment into pivotal Phase…

Even in early stages of disease, people with multiple sclerosis (MS) commonly experience more difficulties performing cognitive and motor tasks simultaneously than do people without MS, a new study indicates. The study, “Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy…

The rates of pregnancy complications are not higher in women with multiple sclerosis (MS) who were using disease-modifying therapies (DMTs) in the earliest stages of pregnancy, a study reported. The study, “Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate or natalizumab in…

The likelihood of survival is about 7.5 times higher for people with multiple sclerosis (MS) who take their disease-modifying treatments as directed compared with those who do not, an analysis of data from U.S. veterans shows. The study, “Impact of Adherence with Disease-Modifying Therapies on All-Cause…

A robot-assisted training program that uses game-like activities to improve upper limb function was met with high satisfaction and enjoyment by people with multiple sclerosis (MS), a small study has found. Most of the participants reported the intervention improved their ability to do day-to-day activities, such as using a…

Treatment with GA Depot, an experimental long-acting form of glatiramer acetate that requires less frequent dosing than approved formulations, significantly reduced relapse rates among people with relapsing forms of multiple sclerosis (MS), according to top-line results from a Phase 3 clinical trial. “We are pleased with the topline…

In people with multiple sclerosis (MS) who show atrophy in a brain region called the thalamus, aerobic fitness is strongly correlated with standardized assessments of cognition and walking ability. However, these associations are not seen for MS patients who don’t have atrophy in the thalamus, according to a new…

The composition of bacteria in the gut is altered in multiple sclerosis (MS) patients compared with healthy people in the same household, a new study reports. That bacterial composition is affected by disease-modifying therapies and seems to be associated with disease severity. These findings could aid in developing…

NurOwn, a stem cell therapy being developed by BrainStorm Cell Therapeutics, showed a good safety profile among people with progressive forms of multiple sclerosis (MS) in an open-label Phase 2 clinical trial, according to new data. The data show the experimental therapy also was associated with promising effects on…

The approved dosage of the multiple sclerosis (MS) therapy Ponvory (ponesimod) — 20 mg taken by mouth once daily — is appropriate for all adults with relapsing forms of MS, a new analysis of data from the OPTIMUM Phase 3 trial found. That analysis showed there was no…

People with multiple sclerosis (MS) have significantly more T-cells equipped with receptors that specifically recognize the Epstein-Barr virus (EBV) than do healthy individuals, a study revealed. Notably, no such differences were detected for T-cells with receptors specifically against other viruses. These findings add to previous data highlighting EBV infection…

In multiple sclerosis (MS), disease-causing immune T-cells enter the brain and spinal cord through the protective soft membranes covering them, called the leptomeninges, a new study shows. The findings “suggest that patients with MS could benefit from immunomodulatory therapies that target the leptomeninges,” the researchers wrote, noting these surrounding…

Long-term treatment with Tysabri (natalizumab) significantly improves cognitive function and increases the chance of disability reduction in people with early relapsing-remitting multiple sclerosis (RRMS), according to data from the four-year observational STRIVE trial. Patients on Tysabri also reported improved quality of life and less impact of MS on…

People with relapsing multiple sclerosis (MS) treated with Tysabri (natalizumab) or Gilenya (fingolimod) are less likely to have disease activity than those on low-efficacy MS medications, according to a small study conducted in Japan. Results also showed that patients receiving the high-efficacy therapies had less brain shrinkage,…

People with secondary progressive multiple sclerosis (SPMS) have more microscopic damage in normal-appearing brain tissue than do patients with relapsing-remitting multiple sclerosis (RRMS), according to a new imaging study. These patients also have a greater number of chronic active lesions than those with RRMS. “Using advanced diffusion MRI…

Abnormalities in the auditory and vestibular systems, which control hearing and balance, are frequently reported among people with multiple sclerosis (MS), a new study found. However, there is a substantial amount of variability in scientific studies that assess these abnormalities, making it difficult to draw an overarching conclusion about…

Treatment with medrysone, a glucocorticoid approved in the U.S. as a topical treatment for certain inflammatory eye diseases, improved repair of myelin in a mouse model of demyelination, a new study shows. The results suggest medrysone may be a useful treatment for multiple sclerosis (MS), which is…

The protective barrier that prevents cells and large molecules from crossing into the central nervous system (CNS) is known to be unusually “leaky” in multiple sclerosis (MS), but targeting a protein called ARF6 can help to stabilize this barrier, a study in mouse models of MS found. Such a treatment…

Treatment with the experimental B-cell depleting therapy ublituximab significantly outperformed Aubagio (teriflunomide) at reducing relapse rates and the number of lesions in people with relapsing forms of multiple sclerosis (MS), according to updated data from the Phase 3 ULTIMATE clinical trials. The two medications had comparable effects…

Aquatic exercise therapy can help to ease fatigue and improve balance in people with multiple sclerosis (MS), without notable side effects, according to a review of published studies. These findings have important implications for MS patients, as fatigue is among the main symptoms of the disease and…

Worldwide, about 22 in every 100,000 people live with secondary progressive multiple sclerosis (SPMS), a review study analyzing data across various countries reported. Its researchers found substantial variability in SPMS rates country-by-country, with countries closer to the poles generally reporting higher prevalence than those near the equator. Rates also…

Publicity in national news outlets and an online self-screening questionnaire helped improve recruitment for a clinical trial in secondary progressive multiple sclerosis (SPMS), a new study highlights. “We have described our experience of recruiting participants with SPMS into two large RCTs [randomized clinical trials] in order to identify areas…

People with multiple sclerosis (MS) who responded to cognitive rehabilitation showed healthier connections between certain brain regions on functional MRI scans than did MS patients who did not respond to the rehab program, a new study reports. These results indicate that certain brain regions need to be working…

In its inaugural issue, a publication from The Gerontological Society of America provides information about recognizing and managing pseudobulbar affect — uncontrolled outbursts of crying or laughing that the authors say are one of the most “underrecognized and undertreated” symptoms of multiple sclerosis (MS) and other neurological conditions. The…

Men with multiple sclerosis (MS) show differences in health-related behaviors based on how much they value certain masculine ideals, according to a new study that suggests possible negative effects of masculinity in terms of seeking medical care. Results from the study — which specifically focused on white males in…